---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-08-18T05:06:01.275494'
end_time: '2026-08-18T05:20:52.539568'
duration_seconds: 891.26
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Dilated Cardiomyopathy 1A
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 35
reference_validation:
  total_references: 35
  verified: 35
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 35
  on_topic: 31
  validator_version: 0.2.1
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Dilated_Cardiomyopathy_1A-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Dilated_Cardiomyopathy_1A-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 1A
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 1A** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Dilated Cardiomyopathy 1A (DCM1A / LMNA Cardiomyopathy): Comprehensive Disease Report

## Summary

**Dilated Cardiomyopathy 1A (DCM1A; OMIM #115200; MONDO:0011541)** is an autosomal-dominant genetic dilated cardiomyopathy caused by heterozygous pathogenic variants in **LMNA**, the gene encoding the nuclear-envelope intermediate filament proteins lamin A and lamin C (1q22). DCM1A is one of the most clinically malignant forms of inherited dilated cardiomyopathy (DCM) because its hallmark is an **arrhythmia-first natural history**: cardiac conduction disease (AV block), atrial arrhythmias (atrial fibrillation with thromboembolic risk), and life-threatening ventricular tachyarrhythmias with high sudden-cardiac-death (SCD) risk typically **precede** overt left-ventricular systolic dysfunction and heart failure. LMNA accounts for roughly 5–6% of DCM and carries the worst prognosis among common DCM genotypes, including the highest heart-transplantation rate (27%) in genotype-phenotype meta-analyses.

Mechanistically, DCM1A arises from a **weakened, mechanically fragile nuclear lamina**. Under the repetitive mechanical strain of the beating heart, lamin A/C-deficient nuclei sustain stress-induced envelope damage, which activates a DNA-damage response, disrupts chromatin organization and mechanotransduction, and dysregulates downstream signaling. Key druggable nodes identified across mouse models and patient-derived iPSC-cardiomyocytes include aberrant **MAPK (ERK/JNK/p38)** and **AKT–mTOR/DUSP4** signaling with impaired autophagy, **PDGF** pathway activation driving calcium-handling arrhythmia, **reactive oxygen species (ROS)** elevation, and **LOXL2**-mediated extracellular-matrix remodeling causing fibrosis. Microtubule-dependent force transmission concentrates mechanical stress on fragile nuclei and is itself a candidate therapeutic target.

Clinical management is dominated by **early, risk-guided ICD implantation** (via validated risk scores such as the van Rijsingen criteria and the Wahbi LMNA-risk-VTA score), device therapy for conduction disease (pacing/CRT), guideline-directed heart-failure pharmacotherapy, anticoagulation for atrial fibrillation, exercise restriction (an actionable gene–environment interaction), and heart transplantation for end-stage disease. Cardiac MRI with late gadolinium enhancement (LGE) is a key diagnostic and prognostic biomarker. **No disease-modifying therapy is approved.** The lead mechanism-targeted candidate, the oral p38α-MAPK inhibitor ARRY-371797 (PF-07265803), showed promise in a 48-week phase 2 study but the confirmatory phase 3 REALM-DCM trial (NCT03439514) was terminated for futility, underscoring the gap between preclinical validation and clinical efficacy in this disease.

---

## Section-by-Section Report

### 1. Disease Information

**Overview.** DCM1A is an inherited dilated cardiomyopathy defined by left-ventricular dilatation and systolic dysfunction in the context of a pathogenic *LMNA* variant, distinguished from other DCM subtypes by prominent, early electrical disease. As stated in a 2026 CMR meta-analysis, *"Lamin A/C (LMNA) cardiomyopathy is an inherited form of dilated cardiomyopathy associated with high rates of arrhythmias, conduction disease and sudden cardiac death, often preceding overt heart failure"* [PMID: 41966904](https://pubmed.ncbi.nlm.nih.gov/41966904/).

**Key identifiers.**
- **OMIM:** #115200 (CMD1A / DCM1A); LMNA gene OMIM 150330
- **MONDO:** MONDO:0011541
- **HGNC gene:** HGNC:6636 (LMNA); NCBI Gene 4000; UniProt P02545
- **ICD-10:** I42.0 (dilated cardiomyopathy, parent term)
- **MeSH:** Cardiomyopathy, Dilated (D002311); Laminopathies
- **Orphanet:** within "Familial isolated dilated cardiomyopathy" / laminopathy spectrum

**Synonyms / alternative names.** LMNA-related dilated cardiomyopathy; LMNA cardiomyopathy; lamin A/C cardiomyopathy; CMD1A; DCM-CD (dilated cardiomyopathy with conduction defect). The disease sits within the broader "laminopathy" spectrum.

**Information source.** The evidence base is largely aggregated disease-level: OMIM/Orphanet curation, multicenter cohorts, genotype-phenotype meta-analyses, mouse models, and patient-derived iPSC studies, supplemented by individual pedigree reports.

---

### 2. Etiology

**Primary cause — genetic.** DCM1A is caused by heterozygous pathogenic variants in *LMNA* (lamin A/C), inherited in an autosomal-dominant pattern. LMNA is pleiotropic; the same gene causes a spectrum of "laminopathies": *"Laminopathies are associated with a wide range of disease phenotypes, including neuromuscular, cardiac, metabolic disorders and premature aging syndromes"* [PMID: 27529282](https://pubmed.ncbi.nlm.nih.gov/27529282/).

**Genetic risk factors / risk stratification.** Within LMNA carriers, specific features confer high arrhythmic risk. In a European cohort of 269 carriers, *"Independent risk factors for MVA were nonsustained ventricular tachycardia, left ventricular ejection fraction <45% at the first clinical contact, male sex, and non-missense mutations (ins-del/truncating or mutations affecting splicing). MVA occurred only in persons with at least 2 of these risk factors"* [PMID: 22281253](https://pubmed.ncbi.nlm.nih.gov/22281253/). **Non-missense variants** (truncating/ins-del/splice) are the highest-risk molecular class.

**Environmental risk factors.** Male sex is associated with higher penetrance and worse outcomes. Intense/competitive exercise is a recognized disease modifier (see Section 5 and gene–environment interaction below). Age is a major factor given age-related incomplete penetrance.

**Protective factors.** No established genetic protective variants are documented for DCM1A. The clearest modifiable protective actions are **avoidance of intense/competitive exercise** and early prophylactic device therapy.

**Gene–environment interactions.** Because pathophysiology is driven by mechanical stress on fragile nuclei, physical strain is biologically expected to accelerate disease. Guidelines single out LMNA (and PKP2): *"The recommendations to engage in intensive exercise and competitive sports are usually contingent on annual clinical surveillance, except for pathogenic variants in specific genes, such as lamin A/C or plakophilin-2"* [PMID: 36929832](https://pubmed.ncbi.nlm.nih.gov/36929832/) — restriction is advised even in genotype-positive, phenotype-negative carriers.

---

### 3. Phenotypes

DCM1A phenotypes are dominated by electrical disease preceding structural/pump failure. Quantitative frequencies from a meta-analysis of 8,097 DCM patients: *"While 73 % of DCM patients with LMNA mutations showed cardiac conduction diseases, low voltage was the reported ECG hallmark in PLN mutation carriers. The frequency of ventricular arrhythmia in DCM patients with LMNA (50 %) and PLN (43 %) mutation"* [PMID: 27576561](https://pubmed.ncbi.nlm.nih.gov/27576561/).

| Phenotype | HPO term (suggested) | Type | Frequency | Onset / course |
|---|---|---|---|---|
| Cardiac conduction defect / AV block | HP:0031546 / HP:0001678 | Clinical sign (ECG) | ~73% | Often first sign, 3rd–4th decade; progressive |
| Ventricular arrhythmia / NSVT | HP:0004308 / HP:0004757 | Clinical sign | ~50% | Adult; high SCD risk |
| Atrial fibrillation | HP:0005110 | Clinical sign | Common | Adult; thromboembolic risk |
| Dilated cardiomyopathy / reduced LVEF | HP:0001644 / HP:0001635 | Physical/structural | Common, mean ~5th decade | Progressive to heart failure |
| Sudden cardiac death | HP:0001645 | Outcome | Elevated | Adult; can precede HF |
| Congestive heart failure | HP:0001635 | Clinical sign | Late | Progressive, end-stage |
| Skeletal myopathy (overlap EDMD/LGMD1B) | HP:0003198 | Sign | Variable/subclinical | Childhood–adult |

**Characteristics.** Age of onset is typically adult (mean DCM onset ~fifth decade), but conduction disease can begin in the 30s. Severity is variable but tends to be severe due to arrhythmia and SCD. Progression is progressive with superimposed episodic arrhythmic events.

**Quality of life.** Reduced functional capacity is measurable by 6-minute walk test and Kansas City Cardiomyopathy Questionnaire (KCCQ); actigraphy in the REALM-DCM trial confirmed reduced real-world physical activity correlating with KCCQ physical-limitation scores [PMID: 41693767](https://pubmed.ncbi.nlm.nih.gov/41693767/).

---

### 4. Genetic / Molecular Information

**Causal gene.** *LMNA* (lamin A/C; HGNC:6636; NCBI Gene 4000; UniProt P02545; chromosome 1q22; gene OMIM 150330; disease OMIM #115200). Lamin A and lamin C are produced by alternative splicing of *LMNA*.

**Variant spectrum.** In a cohort of 324 unrelated DCM patients, LMNA protein-altering variants occurred at **5.9%** frequency [PMID: 18585512](https://pubmed.ncbi.nlm.nih.gov/18585512/). The variant classes: *"Of the 18 alterations, 11 were missense (one present in 2 kindreds), 3 were nonsense, 3 were insertion/deletions, and 1 was a splice site alteration"* [PMID: 18585512](https://pubmed.ncbi.nlm.nih.gov/18585512/) — predominantly heterozygous point mutations distributed across the rod domain and Ig-fold. Recurrent pathogenic variants reported include R190W, R644C, R377H, R89L, and a V445E Ig-fold missense associated with LV non-compaction and reduced sodium current [PMID: 25829471](https://pubmed.ncbi.nlm.nih.gov/25829471/).

**Variant classification (ACMG/AMP).** LMNA variants span pathogenic, likely pathogenic, and VUS in ClinVar. **Non-missense** (truncating/ins-del/splice) alleles confer the highest arrhythmic risk: *"non-missense mutations (ins-del/truncating or mutations affecting splicing)"* [PMID: 22281253](https://pubmed.ncbi.nlm.nih.gov/22281253/).

**Origin.** Germline; typically inherited (familial), occasionally de novo.

**Functional consequence.** Mixed mechanism — haploinsufficiency/loss-of-function combined with dominant-negative effects on nuclear-lamina assembly. Mutant lamin can aggregate subjacent to the nuclear envelope [PMID: 25829471](https://pubmed.ncbi.nlm.nih.gov/25829471/).

**Penetrance / expressivity.** Incomplete and age-related: *"an incomplete and age-related penetrance"* [PMID: 25837155](https://pubmed.ncbi.nlm.nih.gov/25837155/); expressivity is highly variable within families.

**Modifier genes / epigenetics.** LMNA-linked chromatin disorganization implies epigenetic dysregulation; specific modifier alleles are not firmly established, though pedigrees with divergent sub-family phenotypes suggest modifiers [PMID: 29947763](https://pubmed.ncbi.nlm.nih.gov/29947763/). No recurrent chromosomal abnormality defines DCM1A.

---

### 5. Environmental Information

- **Environmental/mechanical factors.** Mechanical strain on fragile nuclei is the dominant "environmental" accelerant. **Intense/competitive exercise** is discouraged in LMNA carriers (see Section 2 gene–environment interaction) [PMID: 36929832](https://pubmed.ncbi.nlm.nih.gov/36929832/).
- **Lifestyle.** Standard cardiovascular risk-factor control applies. Hypertension co-occurs frequently in DCM generally and may modulate severity.
- **Infectious agents.** Not causal for DCM1A. Note the important differential: LMNA-DCM can mimic cardiac sarcoidosis on imaging, and endomyocardial biopsy may be equivocal — genetic testing is essential to distinguish them [PMID: 40225500](https://pubmed.ncbi.nlm.nih.gov/40225500/).

---

### 6. Mechanism / Pathophysiology

**Upstream trigger — nuclear-envelope fragility.** LMNA mutations weaken the nuclear lamina, increasing nuclear-envelope fragility. The causal chain is summarized as: *"LMNA mutations disrupt nuclear envelope stability, activating the DNA damage response (DDR) and compromising chromatin organization and mechanotransduction"* [PMID: 39998502](https://pubmed.ncbi.nlm.nih.gov/39998502/).

**Mechanical force transmission.** The LINC complex (nesprins/SUN proteins) couples the cytoskeleton to the lamina. Microtubule-dependent forces concentrate mechanical stress on lamin-deficient nuclei: *"Microtubule disruption prevented nuclear damage and preserved cardiac function in lamin A/C deficiency"* [PMID: 41073815](https://pubmed.ncbi.nlm.nih.gov/41073815/), identifying microtubule-mediated force as both driver and therapeutic target.

**Downstream signaling — MAPK / AKT–mTOR / DUSP4.** Aberrant ERK1/2 signaling induces DUSP4, activating AKT–mTOR and impairing autophagy: *"Dusp4 expression is enhanced in hearts with LMNA cardiomyopathy, and its overexpression in mice causes it by activating AKT-mTOR signaling that impairs autophagy"* [PMID: 23048029](https://pubmed.ncbi.nlm.nih.gov/23048029/).

**Additional druggable nodes (iPSC-CM evidence).** Patient-derived iPSC-cardiomyocytes reveal calcium-handling arrhythmia driven by PDGF: *"the mutant iPSC-CMs displayed aberrant calcium homeostasis that led to arrhythmias at the single-cell level. Mechanistically, we show that the platelet-derived growth factor (PDGF) signalling pathway is activated in mutant iPSC-CMs"* [PMID: 31316208](https://pubmed.ncbi.nlm.nih.gov/31316208/). ROS elevation contributes downstream [PMID: 39143095](https://pubmed.ncbi.nlm.nih.gov/39143095/), and LOXL2-mediated ECM remodeling drives fibrosis (simtuzumab as candidate inhibitor) [PMID: 41841259](https://pubmed.ncbi.nlm.nih.gov/41841259/).

**Tissue damage.** Myocardial fibrosis (LGE on CMR) is a central downstream lesion, correlating with wall-motion and conduction abnormalities [PMID: 21689390](https://pubmed.ncbi.nlm.nih.gov/21689390/).

**Suggested GO / CL terms.** GO:0006974 (DNA-damage response), GO:0071260 (cellular response to mechanical stimulus), GO:0006914 (autophagy), GO:0000165 (MAPK cascade), GO:0006979 (response to oxidative stress); CL:0000746 (cardiac muscle cell/cardiomyocyte), CL:0002548 (cardiac fibroblast).

**Causal chain (ASCII):**

```
LMNA mutation
   │
   ▼
Weakened nuclear lamina (fragile nucleus)
   │  ── microtubule / LINC-transmitted mechanical force
   ▼
Nuclear-envelope damage → DNA-damage response + chromatin/mechanotransduction disruption
   │
   ├──► ERK/JNK/p38 MAPK ↑ → DUSP4 ↑ → AKT-mTOR ↑ → autophagy ↓
   ├──► PDGF pathway ↑ → aberrant Ca²⁺ handling → single-cell arrhythmia
   ├──► ROS ↑ (oxidative stress)
   └──► LOXL2 ↑ → ECM remodeling → myocardial fibrosis (LGE)
   │
   ▼
Conduction disease + atrial/ventricular arrhythmia  (EARLY)
   │
   ▼
LV dilatation + systolic dysfunction → heart failure  (LATE)
   │
   ▼
Sudden cardiac death / transplantation
```

---

### 7. Anatomical Structures Affected

- **Primary organ:** heart (UBERON:0000948), specifically myocardium/left ventricle (UBERON:0002084), cardiac conduction system (UBERON:0004146).
- **Secondary involvement:** systemic (brain — cardioembolic stroke from AF [PMID: 39687831](https://pubmed.ncbi.nlm.nih.gov/39687831/)); skeletal muscle in overlap laminopathies (paravertebral, glutei, quadriceps, posterior thigh; peroneus involvement helps distinguish EMD- from LMNA-related disease) [PMID: 26573435](https://pubmed.ncbi.nlm.nih.gov/26573435/).
- **Body systems:** cardiovascular (primary), musculoskeletal (overlap), nervous (secondary embolic).
- **Tissue/cell level:** cardiac muscle (striated) and conduction tissue; cardiomyocytes (CL:0000746) and cardiac fibroblasts (CL:0002548).
- **Subcellular:** nuclear envelope/nuclear lamina (GO:0005638 nuclear membrane; GO:0005652 nuclear lamina), nucleus (GO:0005634); secondary involvement of the microtubule cytoskeleton (GO:0005874).
- **Laterality:** left-ventricle predominant, biventricular in advanced disease.

---

### 8. Temporal Development

- **Onset:** adult-onset predominantly; conduction disease may begin in the 3rd–4th decade, with DCM manifesting on average in the 5th decade. Insidious then progressive.
- **Progression / stages:** early = isolated conduction disease / arrhythmia; intermediate = LV dilatation with declining EF; advanced/end-stage = refractory heart failure requiring transplant. Natural history is progressive with superimposed episodic arrhythmic events. A five-generation pedigree documented sinus bradycardia/AV block I° at ~36.5 yr → paroxysmal then permanent AF → NSVT/SCD, with 17 SCDs at mean age 49.3 yr [PMID: 29947763](https://pubmed.ncbi.nlm.nih.gov/29947763/).
- **Patterns:** no spontaneous remission; disease is chronic and lifelong. Critical intervention windows exist for prophylactic ICD (before first malignant arrhythmia) and early CRT in conduction disease [PMID: 38495409](https://pubmed.ncbi.nlm.nih.gov/38495409/).

---

### 9. Inheritance and Population

- **Epidemiology.** DCM overall affects ~1 in 2,500; LMNA accounts for ~5–6% of DCM (5.9% in a 324-proband cohort [PMID: 18585512](https://pubmed.ncbi.nlm.nih.gov/18585512/); 7.5% familial vs 3.6% idiopathic in Parks 2008).
- **Inheritance pattern:** autosomal dominant.
- **Penetrance:** incomplete, age-related [PMID: 25837155](https://pubmed.ncbi.nlm.nih.gov/25837155/).
- **Expressivity:** highly variable, even within families/pedigrees [PMID: 29947763](https://pubmed.ncbi.nlm.nih.gov/29947763/).
- **Natural history/survival:** markedly worse than non-carrier DCM — *"event-free survival at the age of 45 years was 31% versus 75% in non-carriers"* [PMID: 12628721](https://pubmed.ncbi.nlm.nih.gov/12628721/).
- **Sex ratio:** male-biased penetrance; DCM overall M:F ~2.4:1, and even among genotype-positive DCM: *"similar to patients with an identified DCM variant (0.31 [95% CI, 0.26-0.36]; M:F 2.22:1"* [PMID: 39895490](https://pubmed.ncbi.nlm.nih.gov/39895490/). Male sex is itself an arrhythmic risk factor.
- **Founder effects / consanguinity:** not a prominent feature (dominant disease); no strong founder population documented. The concept of "carrier frequency" for a dominant pathogenic variant maps to population variant prevalence — ~0.7% of general-population cohorts harbor any actionable inherited-cardiomyopathy variant across 13 genes [PMID: 35544052](https://pubmed.ncbi.nlm.nih.gov/35544052/).

---

### 10. Diagnostics

**Clinical/functional tests.**
- **ECG / Holter:** first-line — detects AV block, bradyarrhythmia, AF, NSVT (LOINC ECG panels).
- **Echocardiography:** LV dilatation, reduced EF.
- **Cardiac MRI with LGE:** key diagnostic/prognostic biomarker. *"Patients had LV myocardial fibrosis in 88% of cases. Segmental wall motion abnormalities correlated strongly with the degree of enhancement. Myocardial enhancement was associated with conduction abnormalities"* [PMID: 21689390](https://pubmed.ncbi.nlm.nih.gov/21689390/). Meta-analysis: *"The LGE risk ratio for patients with LMNA cardiomyopathy versus healthy controls was 14.39 (P<0.001)"* [PMID: 41966904](https://pubmed.ncbi.nlm.nih.gov/41966904/). Subclinical parametric-mapping changes (prolonged native T1/T2) are present even with preserved EF [PMID: 40372342](https://pubmed.ncbi.nlm.nih.gov/40372342/).
- **Biomarkers:** NT-proBNP tracks heart-failure severity and treatment response.
- **Biopsy:** endomyocardial biopsy may be equivocal and is not required; caution against relying on imaging alone when sarcoidosis is in the differential [PMID: 40225500](https://pubmed.ncbi.nlm.nih.gov/40225500/).

**Genetic testing.** Central to diagnosis. Approach: DCM multigene panel or whole-exome sequencing including *LMNA*; single-gene/cascade testing in families with a known variant. Genetic testing enables accurate etiologic diagnosis, treatment (early ICD), and cascade screening of relatives [PMID: 40225500](https://pubmed.ncbi.nlm.nih.gov/40225500/), [PMID: 29497013](https://pubmed.ncbi.nlm.nih.gov/29497013/).

**Differential diagnosis.** Cardiac sarcoidosis (imaging mimic), other genetic DCM (TTN, FLNC, RBM20, PLN, DSP), arrhythmogenic cardiomyopathy, ischemic cardiomyopathy.

**Screening.** Cascade genetic testing plus serial ECG/Holter/echo/CMR surveillance of at-risk relatives.

---

### 11. Outcome / Prognosis

DCM1A has among the worst prognoses of genetic DCM.

| Prognostic metric | Value | Source |
|---|---|---|
| Event-free survival at age 45 (carriers) | 31% vs 75% non-carriers | [PMID: 12628721](https://pubmed.ncbi.nlm.nih.gov/12628721/) |
| Cardiac conduction disease frequency | ~73% | [PMID: 27576561](https://pubmed.ncbi.nlm.nih.gov/27576561/) |
| Ventricular arrhythmia frequency | ~50% | [PMID: 27576561](https://pubmed.ncbi.nlm.nih.gov/27576561/) |
| Heart-transplant rate (highest of DCM genes) | 27% | [PMID: 27576561](https://pubmed.ncbi.nlm.nih.gov/27576561/) |
| LTVTA incidence in carriers | 19.3–23.4% | [PMID: 31155932](https://pubmed.ncbi.nlm.nih.gov/31155932/) |

**Prognostic factors / risk models.** Two validated tools guide ICD decisions:
- **van Rijsingen criteria** — malignant ventricular arrhythmia (MVA) occurs only with ≥2 of: NSVT, LVEF<45%, male sex, non-missense mutation [PMID: 22281253](https://pubmed.ncbi.nlm.nih.gov/22281253/).
- **Wahbi LMNA-risk-VTA score** (n=839): *"Predictors of LTVTA in the derivation sample were: male sex, nonmissense LMNA mutation, first degree and higher atrioventricular block, nonsustained ventricular tachycardia, and left ventricular ejection fraction"*; C-index 0.776–0.800; available as an online calculator [PMID: 31155932](https://pubmed.ncbi.nlm.nih.gov/31155932/).

**Mortality/morbidity.** High SCD risk (often preceding heart failure), progressive heart failure, and thromboembolic stroke from AF. LGE burden is prognostic.

---

### 12. Treatment

**Standard of care** = guideline heart-failure therapy + device therapy + anticoagulation + transplant, with **no approved disease-modifying drug**.

- **Pharmacotherapy (NCIT interventions):** ACE inhibitors/ARB/ARNI, beta-blockers, mineralocorticoid-receptor antagonists (guideline-directed HF therapy); anticoagulation for AF (stroke prevention).
- **Device therapy:** ICD for SCD prevention (lower threshold than general DCM, guided by risk scores); pacemaker/CRT for conduction disease. Early CRT may preserve EF and delay end-stage HF in LMNA carriers with a pacing/ICD indication [PMID: 38495409](https://pubmed.ncbi.nlm.nih.gov/38495409/).
- **Surgical:** heart transplantation for end-stage disease (highest rate among DCM genotypes).
- **Mechanism-targeted (experimental).** The p38α-MAPK inhibitor **ARRY-371797 (PF-07265803)**: *"ARRY-371797 (PF-07265803), a potent, selective, oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase pathway, improved 6-minute walk test (6MWT) distance in 12 patients with symptomatic LMNA-related DCM in a 48-week, open-label, phase 2 study"* [PMID: 36114020](https://pubmed.ncbi.nlm.nih.gov/36114020/), with reduced NT-proBNP and improved KCCQ [PMID: 36718638](https://pubmed.ncbi.nlm.nih.gov/36718638/). However, *"REALM-DCM was terminated after a planned interim analysis suggested futility"* [PMID: 38979608](https://pubmed.ncbi.nlm.nih.gov/38979608/) (phase 3, NCT03439514).
- **Emerging preclinical targets:** JNK/ERK inhibition, microtubule modulation, PDGFRB inhibition, antioxidants (ROS), and LOXL2 inhibition (simtuzumab) — all validated in models but not yet clinically established.

**Personalized medicine.** Genotype (non-missense vs missense) and the risk scores directly guide ICD timing and exercise counseling.

---

### 13. Prevention

- **Primary prevention:** cannot prevent inheritance of a dominant variant; genetic counseling and reproductive options (PGD/prenatal testing) apply.
- **Secondary prevention:** **cascade genetic screening** of relatives + serial cardiac surveillance (ECG/Holter/echo/CMR) to detect subclinical disease early. CMR parametric mapping can detect preclinical involvement [PMID: 40372342](https://pubmed.ncbi.nlm.nih.gov/40372342/).
- **Tertiary prevention:** early/prophylactic ICD to prevent SCD (risk-score guided); anticoagulation to prevent stroke; **exercise restriction** to slow progression [PMID: 36929832](https://pubmed.ncbi.nlm.nih.gov/36929832/); guideline HF therapy to prevent decompensation.
- **Counseling:** genetic counseling for risk assessment and family planning is a cornerstone.

---

### 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** human *LMNA* (NCBI Gene 4000); mouse *Lmna* (NCBI Gene 16905); orthologs conserved across mammals. Disease mechanisms (nuclear-envelope biology, LINC complex) are evolutionarily conserved.
- **Natural disease in other species:** LMNA/laminopathy-type dilated cardiomyopathy is chiefly modeled experimentally rather than reported as a common spontaneous companion-animal disease; comparative relevance is largely via engineered models. (No specific spontaneous animal disease was confirmed in this investigation.)
- **Zoonotic potential:** none — genetic, non-transmissible.

---

### 15. Model Organisms

**Mouse models (mammalian).**
- **Lmna^H222P/H222P knock-in** — the workhorse autosomal EDMD/DCM model. ERK and JNK MAPK branches are abnormally activated in the heart; pharmacologic inhibition improves cardiac structure/function and fibrosis: *"Echocardiography and histological analysis demonstrated that treatment prevented left ventricular end-systolic dilatation, increased ejection fraction, and decreased myocardial fibrosis"* [PMID: 21173351](https://pubmed.ncbi.nlm.nih.gov/21173351/). ERK inhibition (PD98059) [PMID: 18927124](https://pubmed.ncbi.nlm.nih.gov/18927124/), JNK inhibition (SP600125) [PMID: 20388542](https://pubmed.ncbi.nlm.nih.gov/20388542/), and genetic Erk1 deletion [PMID: 23933734](https://pubmed.ncbi.nlm.nih.gov/23933734/) all improved outcomes. Emerin/Lmna double mutants dissect skeletal- vs cardiac-muscle contributions [PMID: 31430335](https://pubmed.ncbi.nlm.nih.gov/31430335/).
- **Other alleles:** Lmna N195K, LMNA knockout — cardiac conduction/hemodynamic phenotypes.

**Cellular / in vitro (iPSC-CMs).** Patient-derived iPSC-cardiomyocytes recapitulate arrhythmia via aberrant Ca²⁺ handling and PDGF activation [PMID: 31316208](https://pubmed.ncbi.nlm.nih.gov/31316208/); frameshift-LMNA iPSC models show ROS-driven pathology [PMID: 39143095](https://pubmed.ncbi.nlm.nih.gov/39143095/) and LOXL2/ECM remodeling [PMID: 41841259](https://pubmed.ncbi.nlm.nih.gov/41841259/).

**Phenotype recapitulation.** Mouse models reproduce DCM, fibrosis, and MAPK activation well; iPSC-CMs capture cell-autonomous arrhythmia. **Key limitation:** MAPK inhibition rescued mice but the corresponding human phase 3 (REALM-DCM) failed [PMID: 38979608](https://pubmed.ncbi.nlm.nih.gov/38979608/) — a cautionary example of imperfect translational fidelity.

---

## Mechanistic Model / Interpretation

DCM1A is best understood as a **mechanotransduction disease of the cardiomyocyte nucleus**. The primary defect — a structurally weakened nuclear lamina — renders the nucleus vulnerable to the relentless mechanical strain of cardiac contraction. Force is transmitted to the nucleus via the microtubule cytoskeleton and the LINC complex; where lamin A/C is deficient, this force produces stress concentrations and physical envelope damage. The cell responds with a DNA-damage response and pathological signaling — chiefly MAPK (ERK/JNK/p38) feeding DUSP4→AKT–mTOR with impaired autophagy, plus PDGF-driven calcium mishandling, ROS, and LOXL2-driven fibrosis.

Two clinical corollaries follow directly from this model. First, the **arrhythmia-first phenotype** reflects the special vulnerability of the conduction system and the arrhythmogenic consequences of Ca²⁺ dysregulation and progressive fibrosis, which manifest electrically before pump failure. Second, the **exercise-restriction recommendation** is a rational, mechanism-derived intervention: reducing mechanical load reduces nuclear damage. The therapeutic disappointment of p38α inhibition despite strong mouse data suggests that MAPK is one downstream branch of a multi-nodal network; targeting the upstream mechanical driver (microtubules/LINC) or rational combinations (PDGFRB, LOXL2, ROS) may be required.

---

## Evidence Base

| PMID | Role in report | Support / challenge |
|---|---|---|
| [41966904](https://pubmed.ncbi.nlm.nih.gov/41966904/) | Disease definition; LGE prognostic | Supports arrhythmia-first course; LGE RR 14.39 |
| [39998502](https://pubmed.ncbi.nlm.nih.gov/39998502/) | Phenotype spectrum; mechanism | Supports NE/DDR/mechanotransduction chain |
| [22281253](https://pubmed.ncbi.nlm.nih.gov/22281253/) | Risk stratification | Supports van Rijsingen ≥2-factor rule |
| [31155932](https://pubmed.ncbi.nlm.nih.gov/31155932/) | Risk score | Supports LMNA-risk-VTA (C-index 0.78–0.80) |
| [18585512](https://pubmed.ncbi.nlm.nih.gov/18585512/) | Epidemiology/genetics | LMNA 5.9% of DCM; variant classes |
| [12628721](https://pubmed.ncbi.nlm.nih.gov/12628721/) | Natural history | 31% vs 75% event-free survival |
| [39895490](https://pubmed.ncbi.nlm.nih.gov/39895490/) | Sex ratio | Male bias M:F 2.22:1 |
| [23048029](https://pubmed.ncbi.nlm.nih.gov/23048029/) | Mechanism | DUSP4–AKT-mTOR–autophagy |
| [41073815](https://pubmed.ncbi.nlm.nih.gov/41073815/) | Mechanism/therapy | Microtubule force as driver/target |
| [36114020](https://pubmed.ncbi.nlm.nih.gov/36114020/) | Therapy phase 2 | p38α inhibitor 6MWT benefit |
| [38979608](https://pubmed.ncbi.nlm.nih.gov/38979608/) | Therapy phase 3 | **Challenges** MAPK strategy (futility) |
| [21689390](https://pubmed.ncbi.nlm.nih.gov/21689390/) | Diagnostics | 88% LGE fibrosis; ties to conduction |
| [27529282](https://pubmed.ncbi.nlm.nih.gov/27529282/) | Pleiotropy | Laminopathy spectrum |
| [27576561](https://pubmed.ncbi.nlm.nih.gov/27576561/) | Phenotype frequencies | 73% conduction, 50% VA, 27% HTx |
| [36929832](https://pubmed.ncbi.nlm.nih.gov/36929832/) | Gene–environment | Exercise restriction for LMNA |
| [31316208](https://pubmed.ncbi.nlm.nih.gov/31316208/) | iPSC mechanism | PDGF/Ca²⁺ arrhythmia |
| [21173351](https://pubmed.ncbi.nlm.nih.gov/21173351/) | Mouse model | MAPK inhibition rescues phenotype |
| [25837155](https://pubmed.ncbi.nlm.nih.gov/25837155/) | Genetics | Incomplete, age-related penetrance |

---

## Limitations and Knowledge Gaps

1. **Translational gap:** The most striking limitation is that the leading mechanism-targeted therapy (p38α inhibitor) succeeded in mice and phase 2 but failed phase 3 (REALM-DCM), leaving no approved disease-modifying drug and questioning MAPK as a sufficient single target.
2. **Small trial sizes:** Phase 2 (n=12) and phase 3 (n=77) were small for a rare disease, limiting statistical power and generalizability.
3. **Risk-model refinement:** van Rijsingen and Wahbi scores are validated but derived largely from European cohorts; performance across ancestries and in genotype-positive/phenotype-negative carriers needs broader validation.
4. **Penetrance/modifiers:** Incomplete, age-related penetrance and variable expressivity remain poorly explained; specific genetic/epigenetic modifiers are not established.
5. **Epidemiology precision:** Exact population prevalence/incidence of DCM1A specifically (vs DCM overall) is not firmly quantified; carrier-frequency data derive from broad multigene screens.
6. **Animal disease:** Spontaneous natural DCM1A in non-human species is not well documented in this investigation.

---

## Proposed Follow-up Experiments / Actions

1. **Combination-target trials:** Test rational combinations (e.g., MAPK + PDGFRB inhibition, or microtubule/LINC modulation + anti-fibrotic LOXL2 inhibition) in iPSC-CM and Lmna^H222P models before human trials, given the single-node p38 failure.
2. **Upstream mechanical targeting:** Pursue microtubule-directed or LINC-complex therapeutics that reduce nuclear mechanical damage at the source [PMID: 41073815].
3. **Anti-fibrotic strategy:** Advance LOXL2 inhibition (simtuzumab) evaluation informed by CMR-LGE endpoints as a biomarker [PMID: 41841259].
4. **Biomarker-guided prevention trials:** Use subclinical CMR (native T1/T2) to enroll genotype-positive/phenotype-negative carriers into early-intervention/prevention studies [PMID: 40372342].
5. **Prospective risk-model validation:** Validate LMNA-risk-VTA and van Rijsingen scores across diverse ancestries and integrate CMR-LGE quantitatively.
6. **Registry/natural-history studies:** Establish LMNA-specific registries to refine prevalence, penetrance, sex effects, and modifier discovery.
7. **Exercise-intervention evidence:** Prospectively test the effect of activity restriction on disease progression to move the recommendation from mechanistic inference to evidence-based guideline.

---

*Report compiled from a 5-iteration autonomous investigation: 13 confirmed findings, 46 papers reviewed. Evidence types span human clinical cohorts, genotype-phenotype meta-analyses, mouse knock-in models, and patient-derived iPSC-cardiomyocyte studies.*


## Artifacts

- [OpenScientist final report](Dilated_Cardiomyopathy_1A-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Dilated_Cardiomyopathy_1A-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 35 |
| Resolved | 35 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 35 |
| On topic | 31 |
| Off topic | 0 |

All extracted references resolved successfully.